(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
A phase 3 trial testing Bezuclastinib in gastrointestinal stromal tumour, now recruiting.
Overview
(Peak) A Phase 3 Randomised Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumours is a phase 3 interventional study registered as NCT05208047, led by Cogent Biosciences, and recruiting when checked on 2026-09-11. Official title: A Phase 3 Randomised, Open-Label, Multicenter Clinical Study of CGT9486+Sunitinib vs. Sunitinib in Subjects With Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumours. Planned enrolment is 482 participants (estimated). The study started in 2022-04-14 and primary completion is expected in 2025-09-30. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialEfficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
Shares Gastrointestinal stromal tumour (GIST) and the tag ctgov-ingest.
- TrialA Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
Shares Gastrointestinal stromal tumour (GIST) and the tag ctgov-ingest.
- TrialA Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)
Shares Gastrointestinal stromal tumour (GIST) and the tag ctgov-ingest.
- TreatmentCGT4859
Shares Cogent Biosciences and the tag ctgov-ingest.
- TreatmentNB003
Shares Gastrointestinal stromal tumour (GIST) and the tag ctgov-ingest.
- TreatmentIDRX-42
Shares Gastrointestinal stromal tumour (GIST) and the tag ctgov-ingest.
- TreatmentVelzatinib
Shares Gastrointestinal stromal tumour (GIST) and the tag ctgov-ingest.
- TargetKIT
Shares Bezuclastinib, Cogent Biosciences, Gastrointestinal stromal tumour (GIST).